ENO1 and glioma: Survival analyses conducted on TCGA and CGGA datasets revealed that high ENO1 expression correlated with poor prognosis in GBM patients and was significantly upregulated in recurrent gliomas, suggesting its potential as an independent prognostic biomarker.